Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246343 | 0.94 | MEN1 (0.55) | FAAHMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL4239342 | 0.92 | SMN1; SMN2 (0.63) | MEN1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL4244741 | 0.90 | SLC6A5 (0.53) | MEN1KMT2ASMN1; SMN2POLBLTB4R | |
| SCHEMBL5165692 | 0.90 | ADAMTS5 (0.60) | FAAHMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL4251982 | 0.85 | DGAT1 (0.54) | FAAHMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL4243510 | 0.84 | FAAH (0.56) | FAAHMEN1KMT2ALMNATMEM97 | |
| SCHEMBL5182248 | 0.83 | SMN1; SMN2 (0.51) | MEN1KMT2ASMN1; SMN2MAPTPOLB | |
| SCHEMBL4245174 | 0.83 | PARP10 (0.60) | FAAHMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL4239616 | 0.82 | FAAH (0.61) | FAAHMEN1KMT2APOLB | |
| SCHEMBL4242849 | 0.81 | CHRM4 (0.52) | MEN1KMT2ASMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-07-02 | — | — | US | disclosed |
| EP-1771429-A1 | NEW BENZOYL UREA DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | OPRM1, GRIN2C, GRIN3A | FAAH 1415/4885SCN2A 184/4885MEN1 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.